Pink skin, urine and effluent fluid after cyanide poisoning

Sophie Debord, Gael Bourdin, Alina Stoian, Frédérique Bayle, Véronique Leray, Jean-Christophe Richard and Claude Guérin*
*Correspondence: claude.guerin@chu-lyon.fr
Medical Intensive Care and Respiratory Support Hospital, the Croix-Rousse, Lyon, France.

Abstract
We are reporting a fatal case of cyanide intoxication due to voluntary ingestion treated by hydroxycobalamin. Twelve hours after ICU admission abnormal pink colored skin and urines were observed. The effluent fluid removed during the continuous veno-venous hemofiltration treatment also exhibited pink color. Even though pink colored skin and urines is a well-known side-effect of the hydroxycobalamin use as an antidote for cyanide, such an abnormal colour of the effluent fluid has not been previously reported. Contrary to what has been described with the haemodialysis machines whose functioning may be impaired by hydroxycobalamin, the device used to perform continuous renal replacement therapy has worked properly in present case. Therefore, continuous renal replacement therapy should be the first choice method if needed in this setting.

Keywords: Cyanide intoxication, hydroxycobalamine, coloured urines, pink skin, continuous hemofiltration, coloured effluent fluid

Introduction
Severe cyanide intoxication includes cardiac arrhythmias, convulsions and coma occurring shortly after toxic exposure. Indeed, cyanide very rapidly penetrates the cells and binds to the cytochrome c oxidase, resulting in inhibition of mitochondrial respiration and ATP formation. This promotes diffuse tissue hypoxia, metabolic acidosis and increased plasma lactate [1]. Management of severe cyanide intoxication includes: 1) supportive therapy with pure oxygen administration, invasive mechanical ventilation if comatose state or status epilepticus, cardiovascular support and bicarbonate infusion, and 2) antidotes, which should be administered immediately to reverse the combination of cyanide with the cytochrome oxidase. Hydroxycobalamin is an effective antidote as it binds cyanide without the concomitant formation of methemoglobin. It acts rapidly and may improve hemodynamic status. Its side effects are urticaria and red coloured skin and urines, but anaphylactic shock has been reported with hydroxycobalamin use [2]. In the daily civil life, acute cyanide intoxication occurs after smoke inhalation from fire accidents and very rarely from voluntary ingestion [3]. We are reporting the case of a voluntary ingestion of cyanide treated with hydroxycobalamin, in which skin and urines, and also effluent fluid removed during the continuous veno-venous hemofiltration (CVVH) treatment were pink colored. This colour has been attributed to the use of Hydroxycobalamin.

Case Report
A 48-year old male technician in chemical industry, with a past history of psychiatric disorder, committed suicide at his workplace by voluntary ingesting one spoon of cyanide sodium on 10th January 2013 at 2.00 pm. Five minutes later, he presented generalized seizures. The occupational physician called immediately by the fellows of the patient administered 2.5 g Hydroxycobalamin (Cyanokit®) subcutaneously in the left arm. The pre-hospital emergency team (SAMU 69) starts operating at 2.40 pm. The patient was immediately intubated and was receiving an additional 5 g Hydroxycobalamin intravenously. Due to sinusal bradycardia and hypotension, he was given epinephrine as a 1 mg intravenous bolus followed by a 4 mg.h⁻¹ continuous intravenous infusion and 2000 ml isotonic saline intravenous infusion.

At time of ICU admission (3.59 pm), the Glasgow Coma Scale was 3 and both pupils were not reactive to the light stimulation. The following clinical findings were noted: mean arterial pressure 63 mmHg, heart rate with atrial fibrillation and ventricular rate 133.min⁻¹, mottled skin, anuria, cardiac index 2.7 L.min⁻¹.m⁻². The skin of both arms was pink colored (Figures 1A and 1B). Blood chemistry disclosed the followings: pH 6.89, PaCO₂ 34 mmHg, PaO₂ 494 mmHg under F IO₂ 1, arterial lactate 25 mmol.L⁻¹, base excess -25.5 mmol.L⁻¹, sodium 150 mmol.L⁻¹, potassium 3.5 mmol.L⁻¹, bicarbonate 6.5 mmol.L⁻¹, creatinine 104 mcmol.L⁻¹, total calcium 2.04 mmol.L⁻¹, phosphore 3.14 mmol.L⁻¹, total magnesium 1.96 mmol.L⁻¹. Blood coagulation tests were as follows: International Normalized Ratio 1.5, Prothrombin time 54%, platelets count 94 giga.L⁻¹, partial thromboplastin time 2.4 times the control, plasma fibrinogen 2 g.L⁻¹, fibrin degradation products 40 mcg.ml⁻¹. The first Chest-X-ray (4.11 pm) showed bilateral infiltrates in both lung lower lobes. A further 5 g dose of Hydroxycobalamin was given intravenously a few minutes after ICU admission. Continuous intravenous sedation (midazolam 0.07 mg.Kg⁻¹.h⁻¹) and analgesia (morphine chloride 0.07 mg.Kg⁻¹.h⁻¹), together with neuromuscular blockade (cisatracurium 0.18 mg.Kg⁻¹.h⁻¹), were started. Antibiotics including gentamicin, ceftriaxone and metronidazole were given after having sampled blood and lung (fiberoptic broncho-alveolar lavage) for microbiological assessment.
CVVH was started one hour after ICU admission. Pre- and post-dilution substitution fluid was added volume for volume with ultrafiltration loss at a 95 ml.kg.h\(^{-1}\) rate. Within the next 6 hours, the patient received intravenously 5,500 ml Ringer lactate and 250 ml Bicarbonate 4.2%. With the recovery of diuresis twelve hours after ICU admission, the urines were pink colored (Figure 1C). The effluent fluid removed by the CVVH device was also pink colored (Figure 1D). The functioning of the CVVH device was not impaired by this discoloration. The broncho-alveolar lavage done on ICU admission grew 10\(^3\) Units Forming Colony (UFC) Streptococcus hemolyticus, 10\(^5\) UFC Methicillin-Sensitive Staphylococcus aureus, 10\(^5\) UFC Haffnia alvei and 10\(^5\) UFC Stomatococcus. Blood samples were sterile.

Arterial lactate went to normal value (<2 mmol.L\(^{-1}\)) 24 hours after admission but plasma pH and base excess needed a further 36-hour to normalize. However, the patient could not be weaned from the vasoactive support and required CVVH for persistent oliguria. On day 5, abdominal CT scan was indicated for increased arterial lactate and showed right colon ischemia. The patient underwent laparotomy, which confirmed ischemic perforation in the right colon with peritonitis. Right colectomy was performed. The surgical procedure was followed by immediate hemodynamic improvement. The patient remained in comatose state even though sedation had been stopped for several days. Brain Magnetic Resonance Imaging was performed on day 12 of the ICU stay and showed hemorrhagic necrosis of the central grey nuclei with widespread small hemorrhagic foci involving temporal and frontal brain regions. Treatment was withdrawn in accordance with patient's family. The patient eventually died 19 days after ICU admission.

**Discussion**

Cyanide poisoning by suicide is uncommon as compared to that occurring after smoke inhalation [4]. Therefore, the clinicians should be aware of this specific setting for cyanide poisoning in order to administer the antidote without any delay after making clinical suspicion. In our case, the patient committed suicide at his workplace, which was a chemical plant, with a free access to cyanide. Therefore, the suspicion of cyanide poisoning was made easier. Indeed, the company doctor, who was called by the fellow workers of the patient, at time he rushed at the scene of the casualty, was completely aware of what had happened and, hence administered the antidote immediately. In the present case, in spite of an early diagnosis of cyanide poisoning and early antidote administration, the outcome was fatal. In previous reports on suicide attempts by cyanide ingestion some patients may survive [5].

![Figure 1. Pink colored skin of the left forearm (A), where hydrocobalamin was first injected subcutaneously, and of the right forearm (B). Pink colored urine (C), urine and effluent fluid poured from the continuous veno-venous hemofiltration device (D).](image-url)
Hydroxycobalamin is a key component of the management [6] and must be immediately administered once the diagnosis of cyanide poisoning is suspected. It should be mentioned again that the diagnosis is very difficult in case of smoke inhalation. A group of European experts has recently acknowledged hydroxycobalamin as a valid empiric treatment for fire smoke victims [7]. For cyanide salt intoxication, as it occurred in present case, Thompson et al., [8] reviewed the available pharmacological data on hydroxycobalamin and concluded that it was an effective antidote.

Pink colored skin and urine is a common and transient side-effect of hydroxycobalamin use [9-11]. In present case the skin coloration did not look like urticarial and might have resulted from other causes, like hemotama as some blood coagulation disorders were present on admission, or infection. This latter hypothesis seemed unlikely as blood cultures were sterile.

In the present case, we furthermore observed that the effluent fluid during high volume CVVH treatment was also pink colored, a finding that was not previously reported. The colour of the fluid effluent was not associated with any harmful effect. However, it is important to rule out other reasons for pink colored effluent fluid as hemolysis or to rule out filter leaks. Furthermore, it should be noted that the appropriate functioning of the CVVH machine was not impaired by hydroxycobalamin, contrary to what has been reported for the haemodialysis machine [12-14]. In particular hydroxycobalamin can interfere with the blood leak detection device in some haemodialysis machines [12-14]. It is not the mode of renal replacement therapy, namely conventional intermittent haemodialysis or CVVH, that is challenged but the machine used to deliver the mode. Therefore, the use of CVVH should be recommended as the first choice technique to perform renal replacement therapy efficiently in this setting according to the above considerations.

Competing interests
The author’s declare that they have no competing interests.

Authors’ contributions

<table>
<thead>
<tr>
<th>Authors’ contributions</th>
<th>SD</th>
<th>GB</th>
<th>AS</th>
<th>FB</th>
<th>VL</th>
<th>JCR</th>
<th>CG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research concept and design</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Collection and/or assembly of data</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Data analysis and interpretation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Writing the article</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Critical revision of the article</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Final approval of article</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Statistical analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

Received: 09-Jul-2013 Revised: 12-Aug-2013
Re-Revised: 21-Aug-2013 Accepted: 02-Sep-2013
Published: 16-Sep-2013

References


Citation: